Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
02 Novembre 2017 - 2:00AM
Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing
company focused on the development of potentially curative
therapeutics using CRISPR/Cas9 technology, today announced the
pricing of an underwritten public offering of 6,250,000 shares of
its common stock at a public offering price of $24.00 per share,
before underwriting discounts. Intellia also granted the
underwriters a 30-day option to purchase up to an additional
937,500 shares of common stock. The gross proceeds from the
offering, before deducting underwriting discounts and estimated
offering expenses, are expected to be $150 million, excluding any
exercise of the underwriters' option to purchase additional shares.
All of the shares in the offering are to be sold by Intellia.
Credit Suisse, Jefferies LLC, and Leerink Partners are acting as
joint book-running managers of the offering. The offering is
expected to close on or about November 6, 2017, subject to
customary closing conditions.
The shares are being offered by Intellia pursuant to a shelf
registration statement that was previously filed with, and
subsequently declared effective by, the U.S. Securities and
Exchange Commission (SEC). A preliminary prospectus supplement
relating to and describing the terms of the offering was filed with
the SEC on November 1, 2017. The final prospectus supplement
relating to the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
these securities may be obtained, when available, from: Credit
Suisse Securities (USA) LLC, Attn: Prospectus Dept., One Madison
Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by
email at newyork.prospectus@credit-suisse.com; Jefferies LLC, Attn:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, by telephone at 877-547-6340 or by email
at Prospectus_Department@Jefferies.com; or Leerink Partners LLC,
Attn: Syndicate Department, One Federal Street, 37th Floor, Boston,
MA 02110, by telephone at 800-808-7525 ext. 6132 or by
email at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on the development of proprietary, potentially curative
therapeutics using the CRISPR/Cas9 system.
Forward-Looking Statements
This press release contains "forward-looking statements" of
Intellia within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but
are not limited to, those relating to Intellia’s expectations
regarding the anticipated closing of the public offering. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs of future events, and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties related to completion of the public offering on
the anticipated terms, or at all, include, but are not limited to,
market conditions and the satisfaction of customary closing
conditions related to the public offering. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause Intellia’s actual results to
differ from those contained in the forward-looking statements, see
the section entitled “Risk Factors” in Intellia’s most recent
annual report on Form 10-K and quarterly report on Form 10-Q filed
with the SEC, as well as discussions of potential risks,
uncertainties, and other important factors in Intellia’s other
filings with the SEC, including those contained or
incorporated by reference in the preliminary prospectus supplement
related to the public offering filed with the SEC. All information
in this press release is as of the date of the release,
and Intellia undertakes no duty to update this information
unless required by law.
Intellia Contacts:
Jennifer Mound SmoterSenior Vice President, External Affairs
& Communications+1 857-706-1071jenn.smoter@intelliatx.com
Lindsey TrickettVice President, Investor Relations+1
857-285-6211lindsey.trickett@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024